APA (7th ed.) Citation

Xie, S., Xie, S., Yang, L., Yang, L., Yang, L., Zhang, H., . . . Kang, M. (2024, February). Adjuvant therapy provides no additional recurrence-free benefit for esophageal squamous cell carcinoma patients after neoadjuvant chemoimmunotherapy and surgery: A multi-center propensity score match study. Frontiers in Immunology.

Chicago Style (17th ed.) Citation

Xie, Shu-Han, et al. "Adjuvant Therapy Provides No Additional Recurrence-free Benefit for Esophageal Squamous Cell Carcinoma Patients After Neoadjuvant Chemoimmunotherapy and Surgery: A Multi-center Propensity Score Match Study." Frontiers in Immunology Feb. 2024.

MLA (9th ed.) Citation

Xie, Shu-Han, et al. "Adjuvant Therapy Provides No Additional Recurrence-free Benefit for Esophageal Squamous Cell Carcinoma Patients After Neoadjuvant Chemoimmunotherapy and Surgery: A Multi-center Propensity Score Match Study." Frontiers in Immunology, Feb. 2024.